Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Proudfoot, C. A."'
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 11, Pp 117-128 (2019)
Marie Fournier,1 Chieh-I Chen,2 Andreas Kuznik,2 Clare Proudfoot,3 Usha G Mallya,4 Kaleb Michaud5,6 1Health Economics & Value Assessment, Sanofi France, Chilly-Mazarin, France; 2Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 3Sanofi, Guildford,
Externí odkaz:
https://doaj.org/article/8cdf5874e3914c54949d917ae129aaa4
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 10, Pp 805-819 (2018)
Cheryl P Ferrufino,1 Julie Munakata,1 Wenhui Wei,2 Clare Proudfoot,3 Andreas Kuznik,4 Susan H Boklage,4 Chieh-I Chen4 1IQVIA, Fairfax, VA, USA; 2Sanofi, Bridgewater, NJ, USA; 3Sanofi, Guildford, UK; 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, US
Externí odkaz:
https://doaj.org/article/2cb42a7ee40a4d17ae7d3126f41f459d
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 11, Pp 83-85 (2019)
Ferrufino CP, Munakata J, Wei W, et al. Clinicoecon Outcomes Res. 2018;10: 805—819. On page 810, Table 4, Drug costs column, Methotrexate, the Unit WAC was listed as $1 however it should have been $2.36. On page 817, Table S2, the monitoring costs
Externí odkaz:
https://doaj.org/article/b61d1c10d3744f8ab178e730cc4f2551
Autor:
Lafayette, R., Aldworth, C., George, A., Courcy J, De, Golden, K., Kroes, M., Proudfoot, C., Ndife, B.
Publikováno v:
In Value in Health June 2023 26(6) Supplement:S364-S364
Autor:
Lafayette, R., Smeets, S., Kattlun, J., George, A.T., Aldworth, C., Proudfoot, C., Wang, W., de Courcy, J., Yao, L., Roccatello, D.
Publikováno v:
In Kidney International Reports March 2023 8(3) Supplement:S257-S258
Publikováno v:
In Value in Health January 2022 25(1) Supplement:S216-S216
Publikováno v:
In Value in Health January 2022 25(1) Supplement:S115-S115
Publikováno v:
Scopus-Elsevier
Targeted disease-modifying antirheumatic drug (DMARD) options for rheumatoid arthritis (RA) include tumor necrosis factor (TNF) inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab) or alternative mechanisms of action (MOAs), such
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d26b98d49285de18297b2a494b86f2c7
https://europepmc.org/articles/PMC6207310/
https://europepmc.org/articles/PMC6207310/
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
In Value in Health December 2020 23 Supplement 2:S489-S489